Samsung Biologics, Kanaph Therapeutics partner on retinal disease therapy

By The Science Advisory Board staff writers

September 24, 2020 -- Samsung Biologics and Kanaph Therapeutics are partnering on the development of KNP-301, a bispecific Fc fusion protein to treat retinal diseases.

KNP-301 is designed to treat complement-mediated and angiogenesis-driven retinal diseases by suppressing both complement component 3 (C3b) and vascular endothelial growth factor (VEGF) as a bispecific approach. The therapy is the first biologics program out of Kanaph Therapeutics that is preparing for global clinical trials.

Under the agreement, Samsung Biologics will provide full contract development organization services including cell line development, process development, nonclinical and clinical material manufacturing, and investigational new drug submission.

Copyright © 2020

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for